# US 2019/0315847 A1 · Therapeutic combinations using igf1r pathway inhibitors, and methods to predict anti-igf1r therapeutic efficacy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0315847 A1
- Document ID: US20190315847A1
- Status: Published application
- Kind: A1
- Application number: 16/286,021
- Filed: 2019-02-26
- Published: 2019-10-17
- Earliest claimed: 2018-02-26
- Assignees: University of Pittsburgh—Of the Commonwealth System of Higher Education
- Applicants: University Of Pittsburgh-Of The Commonwealth System Of Higher Education
- Inventors: Adrian Lee; Alison Nagle; Steffi Oesterreich
- Web page: https://patentgrep.com/patent/US20190315847A1

## CPC

- C07K 16/22: against growth factors {; against growth regulators}
- A61K 31/138: Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine (atenolol A61K31/165; pindolol A61K31/404; timolol A61K31/5377)
- A61K 31/437: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A61K 31/4985: Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A61K 31/53: having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine (melarsoprol A61K31/555 {; with four nitrogen atoms A61K31/495})
- A61K 31/566: having an oxo group in position 17, e.g. estrone
- A61K 31/7105: Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
- A61P 35/00: Antineoplastic agents
- C12N 15/1138: {against receptors or cell surface proteins}
- G01N 33/5011: {for testing antineoplastic activity}
- G01N 33/57515: of the breast
- C07K 16/2863: {against receptors for growth factors, growth regulators}
- C12N 2310/14: interfering nucleic acids [NA]
- G01N 2333/65: Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
- G01N 2333/705: Assays involving receptors, cell surface antigens or cell surface determinants
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Disclosed herein are methods of treating a subject with an estrogen receptor-positive (ER+) breast cancer comprising obtaining a sample of the breast cancer from the subject; determining a level of E-cadherin in the sample is reduced compared to a control; and administering a therapeutically effective amount of an IGF1R pathway inhibitor and an endocrine therapeutic. Also disclosed herein are methods to treat a cancer in a subject comprising administering a therapeutically effective amount of an IGF1R pathway inhibitor and an E-cadherin inhibitor. Also disclosed are methods to predict the likelihood a subject with a breast cancer will respond therapeutically to a treatment comprising administering an IGF1R pathway inhibitor, the method comprising obtaining a sample of the cancer from the subject; and determining a level of E-cadherin in the sample.

## Claims

### Claim 1

A method of treating a subject with a cancer comprising:
a) obtaining a sample of the cancer from the subject;
b) determining a level of E-cadherin in the sample is reduced compared to a control; and
c) administering a therapeutically effective amount of an IGF1R pathway inhibitor and an endocrine therapeutic.

### Claim 2 (depends on 1)

The method of claim 1, wherein the cancer comprises an estrogen receptor-positive (ER+) breast cancer.

### Claim 3 (depends on 2)

The method of claim 2, wherein the control comprises one or more non-cancerous mammary epithelial cells of the subject.

### Claim 4 (depends on 2)

The method of claim 2, wherein the ER+ breast cancer comprises an invasive lobular breast cancer (ILC).

### Claim 5 (depends on 1)

The method of claim 1, wherein the IGF1R pathway inhibitor comprises MEDI-573, OSI-906, BMS-754807, BEZ235, xentuzumab, or a combination thereof.

### Claim 6 (depends on 1)

The method of claim 1, wherein the endocrine therapeutic comprises tamoxifen, ICI 182,780, or a combination thereof.

### Claim 7 (depends on 1)

The method of claim 1, wherein the level of E-cadherin is reduced by at least 50% compared to the control.

### Claim 8 (depends on 1)

The method of claim 1, wherein the determining step comprises determining a level of E-cadherin polypeptide expression.

### Claim 9

A method of treating a cancer in a subject comprising administering a therapeutically effective amount of an IGF1R pathway inhibitor and an E-cadherin inhibitor.

### Claim 10 (depends on 9)

The method of claim 9, wherein the cancer in the subject comprises a level of E-cadherin which is not reduced compared to a control.

### Claim 11 (depends on 9)

The method of claim 9, wherein the IGF1R pathway inhibitor comprises MEDI-573, OSI-906, BMS-754807, BEZ235, xentuzumab, or a combination thereof.

### Claim 12 (depends on 9)

The method of claim 9, wherein the E-cadherin inhibitor comprises a small interfering RNA (siRNA), a short hairpin RNA (shRNA), or a combination thereof.

### Claim 13 (depends on 9)

The method of claim 9, wherein the cancer comprises a breast cancer.

### Claim 14 (depends on 15)

The method of claim 15, wherein the cancer comprises an invasive ductal breast carcinoma (IDC).

### Claim 15 (depends on 9)

The method of claim 9, further comprising obtaining a cancerous tissue sample from the subject and detecting the level of E-cadherin in the sample.

### Claim 16 (depends on 15)

The method of claim 15, wherein the level of E-cadherin is the level of E-cadherin polypeptide expression.

### Claim 17 (depends on 15)

The method of claim 15, wherein the control comprises one or more non-cancerous cells of the subject which are of a same cell type as a cell of the sample.

### Claim 18

A method of increasing the sensitivity of a cancer in a subject to an IGF1 pathway inhibitor comprising administering to the subject a therapeutically effective amount of an E-cadherin inhibitor.

### Claim 19

A method of detecting sensitivity of a cancer to IGF1R pathway inhibition in a subject comprising obtaining a cancerous tissue sample; and assaying the level of E-cadherin in the tissue sample relative to a control; wherein a decrease in the level of E-cadherin indicates that the cancer is sensitive to IGF1R inhibition.

### Claim 20 (depends on 19)

The method of claim 19, wherein the level of E-cadherin is determined by measuring the level of E-cadherin polypeptide expression.

### Claim 21

A pharmaceutical composition comprising an IGF1R pathway inhibitor and an E-cadherin inhibitor.

### Claim 22 (depends on 21)

The pharmaceutical composition of claim 21, wherein the IGF1R pathway inhibitor comprises MEDI-573, OSI-906, BMS-754807, BEZ235, xentuzumab, or a combination thereof.

### Claim 23 (depends on 21)

The pharmaceutical composition of claim 21, wherein the E-cadherin inhibitor comprises a small interfering RNA (siRNA), a short hairpin RNA (shRNA).

### Claim 24

A pharmaceutical composition comprising an IGF1R pathway inhibitor and an endocrine therapeutic.

### Claim 25 (depends on 24)

The pharmaceutical composition of claim 24, wherein the IGF1R pathway inhibitor comprises MEDI-573, OSI-906, BMS-754807, BEZ235, xentuzumab, or a combination thereof.

### Claim 26 (depends on 24)

The pharmaceutical composition of claim 24, wherein the endocrine therapeutic comprises tamoxifen, ICI 182,780, or a combination thereof.
